HPB is taking Cylert (pemoline) off the market in Canada
HPB is taking Cylert (pemoline) off the market in Canada.
They say the risk of severe liver toxicity outweighs the benefits of using Cylert for Attention Deficit Hyperactivity Disorder (ADHD). Liver failure from Cylert can result in transplants and even death.
Patients who really need Cylert can still get it through Health Canada's Special Access Program.